| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BRCC3 |
| Uniprot No | P46736 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-316aa |
| 氨基酸序列 | AVQVVQAVQAVHLESDAFLVCLNHALSTEKEEVMGLCIGELNDDTRSDSKFAYTGTEMRTVAEKVDAVRIVHIHSVIILRRSDKRKDRVEISPEQLSAASTEAERLAELTGRPMRVVGWYHSHPHITVWPSHVDVRTQAMYQMMDQGFVGLIFSCFIEDKNTKTGRVLYTCFQSIQAQKSSESLHGPRDFWSSSQHISIEGQKEEERYERIEIPIHIVPHVTIGKVCLESAVELPKILCQEEQDAYRRIHSLTHLDSVTKIHNGSVFTKNLCSQMSAVSGPLLQWLEDRLEQNQQHLQELQQEKEELMQELSSLE |
| 预测分子量 | 51.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BRCC3重组蛋白的3篇参考文献概览(文献信息为模拟示例，非真实存在)：
1. **文献名称**：*Structural and functional analysis of BRCC3 in the BRCA1-A complex*
**作者**：Smith A, et al.
**摘要**：解析了BRCC3重组蛋白的晶体结构，发现其作为去泛素化酶通过结合BRCA1调控DNA损伤修复，突变体实验表明其活性位点对修复功能至关重要。
2. **文献名称**：*BRCC3-mediated regulation of inflammatory signaling in macrophages*
**作者**：Li X, et al.
**摘要**：研究表明，重组BRCC3通过调控NLRP3炎症小体的泛素化状态影响炎症反应，敲除BRCC3导致巨噬细胞中IL-1β分泌异常。
3. **文献名称**：*BRCC3 promotes oncogenic growth via HIF-1α stabilization in breast cancer*
**作者**：Wang Y, et al.
**摘要**：发现BRCC3重组蛋白通过去泛素化HIF-1α增强其稳定性，促进乳腺癌细胞在缺氧条件下的增殖和侵袭，提示其作为潜在治疗靶点。
4. **文献名称**：*In vitro reconstitution of the BRCA1-BRCC3 deubiquitinating enzyme complex*
**作者**：Johnson R, et al.
**摘要**：利用重组BRCC3蛋白在体外重构BRCA1复合体，证实其与ABRAXAS和MERIT40的相互作用对复合体酶活性和底物识别至关重要。
(注：以上文献为模拟内容，实际研究中请通过PubMed或Web of Science检索真实文献。)
**Background of BRCC3 Recombinant Protein**
BRCC3 (BRCA1/BRCA2-containing complex subunit 3) is a deubiquitinating enzyme belonging to the JAMM/MPN+ metalloprotease family. It plays a critical role in regulating protein stability and signaling pathways, particularly through its involvement in the BRCA1-A complex and the BRISC complex. In the BRCA1-A complex, BRCC3 modulates DNA repair processes by deubiquitinating γH2AX, a key histone marker for DNA damage response. Within the BRISC complex, it regulates inflammatory signaling by cleaving Lys63-linked ubiquitin chains on targets like interferon receptors, influencing type I interferon signaling and immune responses.
Mutations or dysregulation of BRCC3 have been linked to several diseases, including cancer, autoimmune disorders, and thrombocytopenia. For instance, loss-of-function mutations in BRCC3 are associated with premature ovarian insufficiency and disrupted DNA repair mechanisms, while its overexpression in certain cancers may contribute to tumor progression.
Recombinant BRCC3 protein is produced using engineered expression systems (e.g., *E. coli* or mammalian cells) to ensure proper folding and enzymatic activity. This tool enables researchers to study BRCC3's structural and functional properties, screen for inhibitors or activators, and explore its role in disease mechanisms. Its applications extend to *in vitro* assays, structural studies, and drug discovery efforts aimed at targeting BRCC3-related pathways in cancer or inflammation.
Overall, BRCC3 recombinant protein serves as a vital resource for unraveling the enzyme’s biological significance and therapeutic potential in human health and disease.
×
